These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22820661)

  • 1. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
    Gao FF; Krasinskas AM; Chivukula M
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
    Barbieri PG
    Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
    [No Abstract]   [Full Text] [Related]  

  • 16. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM; Franke FE; Müller KM
    Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.